octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed...

Descripción completa

Detalles Bibliográficos
Autores principales: Klukowska, Anna, Komrska, Vladimír, Vdovin, Vladimír, Zozulya, Nadezhda, Lissitchkov, Toshko, Oldenburg, Johannes, Ettingshausen, Carmen Escuriola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171997/
https://www.ncbi.nlm.nih.gov/pubmed/32341775
http://dx.doi.org/10.1177/2040620720914692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171997/
https://www.ncbi.nlm.nih.gov/pubmed/32341775
http://dx.doi.org/10.1177/2040620720914692

Ejemplares similares